CAR-T in Autoimmune Diseases

Moffitt Cancer Center

A. Mirza

Cellular Therapy in 2024: What, Why, When, Who… and Where Are We Goi…

University of Colorado Department of Medicine

J. Gutman

Interventional Treatment of Hepatocellular Carcinoma: Combination of…

Thomas Vogl

Infectious Disease Perspective of CAR T-Cell Therapy

Moffitt Cancer Center

A. Baluch

CAR T-Cell Therapy in Autoimmune Disorders

Vanderbilt University Medical Center (VUMC)

O. Oluwole

Y90 Radioembolization for Locally Advanced HCC

UCLA Health

S. Padia

ASH 2024 Summary: Late Complications and Long-Term Care for Adult Pt…

2024 ASH Annual Meeting Insights Hub

M. Bishop

The Expanding World of CAR T-Cell Therapy

UNC Lineberger Comprehensive Cancer Center

F. Brianne Buchanan

Drug Allergy

Mariana Castells

Endocrine Adverse Events From Checkpoint Inhibitors

Yale Cancer Center

K. Herold

Future Targets for Cell Therapy in Lung Cancer: Breaking the Glass C…

Moffitt Cancer Center

B. Creelan

Low Dose TBI Improves CD19 CAR-T Expansion, Persistence, and Traffic…

Memorial Sloan Kettering Cancer Center

M. Alhomoud

Tandem 2025 Insights: Clonal Hematopoiesis Underlies Prolonged Cytop…

Insights from 2025 Tandem Annual Meeting

H. Hosoya

Understanding and Managing ICANS - Neurological Toxicity in CAR-T Im…

The Immuno-Oncology Clinical Network (IOCN)

F. Vonberg

CAR NK Cells: Next Generation Cell Therapies for Cancer

University of Colorado Cancer Center

K. Rezvani

CAR T-Cell vs. Bispecific Therapies for Blood Cancers: How Oncologis…

GRACE

A. Goodman, A. Jeong, S. Rajeeve

ASH 2024 Treatment Updates on T-Cell Engagers: A Tale of Two Bindings

UChicago Medicine

E. Bauer, A. Heitman

SIR 2024 Insights: Route90 US IDE Pivotal Study Early Results in Rad…

SIR 2024 Insights

A. Kennedy

Point-of-Care CAR-T Manufacturing

Moffitt Cancer Center

N. Kekre

HCC Percutaneous Radio-Ablation Using BAT-90: Results of an Ongoing …

Malkhaz Mizandari